Trump and Musk are obsessed with genetics – but there’s no science behind their simplistic views
By Jonathan Roberts,
The Guardian
| 12. 30. 2024
“Donald Trump speaking with supporters at a campaign rally at the Prescott Valley Event Center in Prescott Valley, Arizona” by Gage Skidmore licensed under CC by SA 2.0
Like so many of us, I was dispirited to wake up a few weeks ago to learn that Donald Trump will be back in the White House. This time he was aided by the world’s richest man and professional spaceship-crasher, Elon Musk. Among the many charming aspects of their partnership is a fondness for some highly unsavoury views on genetics. Trump is an enthusiastic advocate of “racehorse theory”, which he shares with white supremacists; the belief that he is personally superior and that this is rooted in his “good genes”. It’s a vapid idea, but it directly informs his toxic views on immigration, where he argues the country needs to be shielded from the “bad genes” of outsiders.
Meanwhile, Musk has his own equally baffling take on genetics, infused with a characteristic messiah complex. Like some of his fellow tech moguls, he is determined to “save humanity” by ...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...